Patents by Inventor Hairong Zhou

Hairong Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BATTERY CELL, BATTERY, AND ELECTRIC APPARATUS
    Publication number: 20250070426
    Abstract: A battery cell, a battery, and an electric apparatus are described. A sampling module is connected to a housing and electrically connected to a conductor. At least one conductor is disposed on the housing and electrically connected to an electrode terminal. When status signals from the battery cell are collected, signals from at least one collection point of the sampling module are directly transmitted by the electrode terminal. In this way, the sampling module is integrated on the end cover and at least one conductor is electrically connected to the electrode terminal, which changes the conventional method of transmitting signals to CMC through a flexible circuit board and wiring harness, avoids the transmission of status signals from being affected by factors such as interference coupling and wiring harness short-circuiting, shortens the signal transmission path, and improves the reliability of signal collection by the sampling module.
    Type: Application
    Filed: November 14, 2024
    Publication date: February 27, 2025
    Applicant: CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED
    Inventors: Hairong KANG, Jia HE, Chenling ZHENG, Chong WANG, Fangjie ZHOU
  • TEMPERATURE MEASURING METHOD AND APPARATUS BASED ON CREATINE CHEMICAL EXCHANGE SATURATION TRANSFER IMAGING
    Publication number: 20250031975
    Abstract: A temperature measuring method and apparatus based on creatine chemical exchange saturation transfer (CEST) imaging. The method comprises the following steps: (1) performing creatine CEST imaging on a creatine phantom, and analyzing a chemical shift of creatine relative to water in the creatine phantom; (2) fitting a mathematical relation between the chemical shift of the creatine relative to water and the temperature; and (3) performing CEST imaging on creatine in a sample, and calculating the temperature according to the mathematical relation, fitted in step (2), between the chemical shift of the creatine relative to water and the temperature. In the temperature measuring method, the creatine is taken as an endogenous reference, and highly-spatial-resolution, highly-sensitive, and non-invasive absolute temperature measurement can be implemented by means of temperature dependence of a CEST effect of Cr and water.
    Type: Application
    Filed: January 19, 2022
    Publication date: January 30, 2025
    Applicant: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY
    Inventors: Lijuan Zhang, Chao Zou, Siqi Cai, Shihui Zhou, Yang Zhou, Hairong Zheng, Xin Liu
  • Pyrimido[5,4-d]pyrimidines derivatives as irreversible inhibitors of tyrosine kinases
    Patent number: 7786131
    Abstract: The present invention relates to pyrimido [5,4-d] pyrimidine compounds of Formula II or a pharmaceutically acceptable salt thereof, wherein Q is and X, E1, E2, E3, R6 and p are as defined herein. The compounds of this invention are irreversible inhibitors of tyrosine kinases and are useful in the treatment of cancer, atherosclerosis, restenosis, endometriosis and psoriasis.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: August 31, 2010
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
  • 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
    Patent number: 7456168
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: November 25, 2008
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES
    Publication number: 20070179118
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Application
    Filed: April 11, 2007
    Publication date: August 2, 2007
    Inventors: Mark Barvian, Richard Booth, John Quin, Joseph Repine, Derek Sheehan, Peter Toogood, Scott Vanderwel, Hairong Zhou
  • 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
    Patent number: 7208489
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: April 24, 2007
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
    Patent number: 6936612
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: August 30, 2005
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones
    Publication number: 20050137214
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Application
    Filed: January 28, 2005
    Publication date: June 23, 2005
    Inventors: Mark Barvian, Richard Booth, John Quin, Joseph Repine, Derek Sheehan, Peter Toogood, Scott Vanderwel, Hairong Zhou
  • Irreversible inhibitors of tyrosine kinases
    Publication number: 20030229051
    Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.
    Type: Application
    Filed: May 20, 2003
    Publication date: December 11, 2003
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalker, Jeffrey B. Smaill, Hairong Zhou
  • Antidiabetic agents
    Publication number: 20030171377
    Abstract: The present invention provides compounds of Formula (I): 1
    Type: Application
    Filed: August 22, 2002
    Publication date: September 11, 2003
    Inventors: Christopher Franklin Bigge, Alexander James Bridges, Agustin Casimiro-Garcia, Stephen Alan Fakhoury, Helen Tsenwhei Lee, Jessica Reed, Robert Schaum, Kevin Matthew Schlosser, Karen Sexton, Hairong Zhou
  • 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
    Publication number: 20030149001
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Application
    Filed: January 16, 2003
    Publication date: August 7, 2003
    Inventors: Mark Barvian, Richard John Booth, John Ouin, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • Irreversible inhibitors of tyrosine kinases
    Patent number: 6602863
    Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: August 5, 2003
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
  • Irreversible inhibitors of tyrosine kinases
    Patent number: 6344459
    Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: February 5, 2002
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
  • 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
    Patent number: RE47739
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: November 26, 2019
    Assignee: Warner-Lambert Company LLC
    Inventors: Mark Barvian, Richard John Booth, John Quinn, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Lawrence Toogood, Scott Norman Vanderwel, Hairong Zhou